Literature DB >> 9141972

Reversible severe hereditary hemochromatotic cardiomyopathy.

T A Madani1, J Bormanis.   

Abstract

Two cases of severe hereditary hemochromatotic cardiomyopathy are reported. Both patients responded remarkably well to treatment and are leading a normal life requiring no cardiac medications, following small volume phlebotomies for two years combined, in the first three and six months of treatment, with subcutaneous deferoxamine mesylate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141972

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  1 in total

1.  A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

Authors:  Pradyumna Phatak; Pierre Brissot; Mark Wurster; Paul C Adams; Herbert L Bonkovsky; John Gross; Peter Malfertheiner; Gordon D McLaren; Claus Niederau; Alberto Piperno; Lawrie W Powell; Mark W Russo; Ulrich Stoelzel; Wolfgang Stremmel; Louis Griffel; Nicola Lynch; Yiyun Zhang; Antonello Pietrangelo
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.